Skip to content
Bamboo WorksBamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

autoimmune disease

BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales

InnoCare Pharma Ltd. (9969.HK; 688428.SH) said on Thursday its revenue rose 37% last year to 1.01 billion yuan ($138 million), fueled by strong gains for Orelabrutinib, its drug used to…
January 17, 2025
9969.HK 688428.SHG

Recent Articles

January 17, 2025

BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales

9969.HK 688428.SHG

RECENT ARTICLES

  1. January 21, 2025
    BRIEF: InnoCare, KeyMed in antibody licensing agree with Prolium
    9969.HK 688428.SHG
  2. March 6, 2025
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  3. February 6, 2025
    After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
    2696.HK
  4. April 1, 2025
    DPC Dash serves up banner 2024 topped with milestones
    1405.HK
  5. March 25, 2025
    Horizon’s lead grows in smart driving race with new product rollouts
    9660.HK
  6. March 7, 2025
    Dingdong rings up strong end to 2024, but warns of turbulence ahead
    DDL.US
  7. March 10, 2025
    After profit plunge in 2024, Maoyan spotlights strong start to 2025
    1896.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.